Brii Bio, a Chinese company committed to serving patients’ needs and improving public health, announced its launch with significant partnerships and financing. Brii Bio aims to accelerate the development and delivery of breakthrough medicines through partnerships, best-in-class research and development, and the disruptive application of digital and data insight.
Brii, which stands for breakthrough innovation and insight, launches with three foundational and strategic partnerships that will accelerate infectious disease drug development and commercialization in China and leverage technology and data to drive improvements to the Chinese healthcare system and outcomes for patients.
A partnership with Vir, a leading U.S.-based biotech focused on infectious diseases, will grant Brii Bio options on exclusive greater China rights for up to four assets in Vir’s portfolio. This therapeutic pipeline holds the potential to prevent, treat and cure a wide range of infectious diseases.
A first-of-its-kind digital and data insight partnership with AliHealth, the healthcare arm of Alibaba Group to collaborate and explore disruptive approaches to optimize clinical and commercial development efforts by capturing value evidence and improving patients’ experience with new therapies. This partnership will also explore ways to accelerate the uptake of new medicines and support appropriate use of new medicines.
In addition to the Vir and AliHealth partnerships, Brii Bio has entered into a memorandum of understanding with WuXi AppTec and WuXi Biologics for priority access to WuXi’s research and development capabilities.
The company is headquartered in China and the United States, with offices in Shanghai, Beijing, San Francisco, and Durham, North Carolina.